JP Morgan Chase’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

JP Morgan Chase’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-27,000	Closed	-$1.98M	–	7827
2024 Q3	$1.98M	Sell	27,000 -30,300	-53%	-$2.28M	﹤0.01%	4018
2024 Q2	$3.92M	Buy	+57,300	New	+$3.97M	﹤0.01%	3230
2024 Q1	–	Sell	-4,200	Closed	-$301K	–	7968
2023 Q4	$301K	Buy	+4,200	New	+$242K	﹤0.01%	5102
2021 Q1	–	Sell	-79,500	Closed	-$2.53M	–	6422
2020 Q4	$2.53M	Buy	+79,500	New	+$2.09M	﹤0.01%	3313
2019 Q3	–	Sell	-154,800	Closed	-$1.97M	–	6003
2019 Q2	$1.97M	Buy	+154,800	New	+$1.99M	﹤0.01%	3389
2016 Q4	–	Sell	-90,000	Closed	-$1.37M	–	5169
2016 Q3	$1.37M	Buy	+90,000	New	+$3.64M	﹤0.01%	2989

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

JP Morgan Chase's ITCI Position: Q2 2025 in Review

JP Morgan Chase sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 759,991 shares — an estimated $100M sold.

JP Morgan Chase first reported a position in ITCI in Q4 2015 and held it in 37 quarters. The position peaked at $428M in Q4 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

JP Morgan Chase reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
JP Morgan Chase sold 759,991 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $100M.
JP Morgan Chase first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 37 quarters.
JP Morgan Chase's Intra-Cellular Therapies Inc. position peaked at $428M in Q4 2024.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.